CrystalGenomics aiming to take on celecoxib as novel COX-2 inhibitor moves forward
This article was originally published in Scrip
CrystalGenomics has begun a US Phase IIb trial for its most advanced development project CG100649, a "next-generation" COX-2 inhibitor it believes has benefits over the current big sellers in the class such as celecoxib (Pfizer's Celebrex).
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.